secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0000950170-24-087501
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Device Designation for Fractyl's Revita in weight maintenance after GLP-1 discontinuation
--------------------------------------------------------------------------------

- Revita targets duodenal lining; aims to maintain weight loss after stopping GLP-1 drugs.
- Breakthrough Device Designation enables priority FDA review and potential CMS reimbursement support.
- REMAIN-1 pivotal study underway; data readouts expected starting Q4 2024, mid-point analysis Q2 2025.
- Designation based on prior pooled weight data from T2D studies showing durable weight maintenance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024087501/0000950170-24-087501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024087501/guts-20240729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-087501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer